Orrick, Arent Rep Par Pharma In $410M Anchen Buy

Law360, New York (August 24, 2011, 11:33 AM EDT) -- Par Pharmaceutical Cos. Inc. announced Wednesday it would pay $410 million in cash for generic-drug maker Anchen Pharmaceuticals Inc., a privately held outfit that has aggressively challenged patents for brand-name drugs.

Irvine, Calif.-based Anchen prides itself in its "creativity and speed in filling abbreviated new drug applications"  in order to make products "that avoid patents covering branded products.'

"This transaction accelerates the expansion of Par's research and development infrastructure and reinforces our strategy to provide long-term sustainable growth," Par CEO Patrick G. LePore said.

Par said...
To view the full article, register now.